NBY: יחס שווי שוק לערך בספרים NovaBay Pharmaceuticals

The current market value of NovaBay Pharmaceuticals (NBY) shown on this chart is fixed at -0.86. The business is protected by composition patents, while strict regulatory oversight and close ties with pharmacies create high barriers to entry. The company is currently restructuring its liabilities, divesting from loss-making beauty projects to focus on the development of ophthalmology. Growth is driven by the Avenova brand, which offers antimicrobial agents to combat dry eye.

Fundamental risks for NovaBay Pharmaceuticals (NBY) are determined by the gap between market value and net assets. For a company developing the Avenova hygiene standard, the assessment of capitalization relative to equity is critical. The history of the market capitalization-to-book value ratio demonstrates the extent to which the market has overvalued the business. This metric compares the current share price with the book value, revealing hidden undervaluation or overheating. A sharp decline in this trajectory signals credit threats and the risk of frozen investments.